Molecular modelling, synthesis and acetylcholinesterase inhibition of ethyl 5-amino-2-methyl-6,7,8,9-tetrahydrobenzo[b][1,8]naphthyridine-3-carboxylate

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 9, 2010, Pages 2950-2953

  Soriano, Elena ^a   Samadi, Abdelouahid ^a   Chioua, Mourad ^a   Ríos, Cristóbal de los ^b   Marco Contelles, José ^a  

^a INSTITUTO DE QUÍMICA ORGÁNICA GENERAL   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

AChE BuChE inhibition; Alzheimer's disease; Ethyl 5 amino 2 methyl 6,7,8,9 tetrahydrobenzo b 1,8 naphthyridine 3 carboxylate; Molecular modelling

Indexed keywords

ACETYLCHOLINESTERASE; CARBOXYLIC ACID DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETHYL 5 AMINO 2 METHYL 6,7,8,9 TETRAHYDROBENZO[B][1,8]NAPHTHYRIDINE 3 CARBOXYLATE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; MOLECULAR MODEL;

ACETYLCHOLINESTERASE; BINDING SITES; CHOLINESTERASE INHIBITORS; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; NAPHTHYRIDINES;

EID: 77950857988     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.03.010     Document Type: Article

References (24)

1. Whitehouse P.J., Price D.L., Clark A.W., Coyle J.T., and DeLong M.R. Ann. Neurol. 10 (1981) 122
2. Neve R.L., McPhie D.L., and Chen Y. Brain Res. 886 (2000) 54
3. Crowther R.A., and Goedert M.J. Struct. Biol. 130 (2000) 271
4. Cummings J.L. Rev. Neurol. Dis. 1 (2004) 60
5. Scarpini E., Scheltens P., and Feldman H. Lancet Neurol. 2 (2003) 539
6. Bartus R., Dean R., Beer B., and Lippa A. Science 217 (1982) 408
7. Ronco C., Sorin G., Nachon F., Foucault F., Jean L., Romieu A., and Renard P.-Y. Bioorg. Med. Chem. 17 (2009) 4523
8. Barreiro E.J., Camara C.A., Verli H., Brazil-Más L., Castro N.G., Cintra W.M., Aracava Y., Rodrigues C.R., and Fraga C.A.M.J. Med. Chem. 46 (2003) 1144
9. Hu M.-K.J. Pharm. Pharmacol. 53 (2001) 83
10. Desai, M. C. Patent Appl. U.S. 1993 520440.
11. León R., de los Ríos C., Marco-Contelles J., Huertas O., Barril X., Luque F.J., López M.G., García A.G., and Villarroya M. Bioorg. Med. Chem. 16 (2008) 7759
12. Marco J.L., de los Ríos C., García A.G., Villarroya M., Carreiras M.C., Martins C., Eléuterio A., Morreale A., Orozco M., and Luque F.J. Bioorg. Med. Chem. 12 (2004) 2199
13. Harel M., Schalk I., Ehret-Sabatier L., Bouet F., Goeldner M., Hirth C., Axelsen P.H., Silman I., and Sussman J.L. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 9031
14. There are small structural changes at the catalytic binding site between TcAChE and hAChE except for those of Tyr337 (in hAChE; Phe330 in Torpedo californica AChE, TcAChE).
15. Wlodek S.T., Antosiewicz J., and Briggs J.M.J. Am. Chem. Soc. 119 (1997) 8159
16. Bartolucci C., Perola E., Pilger C., Fels G., and Lamba D. Proteins 42 (2001) 182
17. Raves M.L., Harel M., Pang Y.-P., Silman I., Kozikowski A.P., and Sussman J.L. Nat. Struct. Biol. 4 (1997) 57
18. Camps P., El Achab R., Morral J., Muñoz-Torrero D., Badía A., Baños J.E., Vivas N.M., Barril X., Orozco M., and Luque F.J.J. Med. Chem. 43 (2000) 4657
19. Goldfarb, D. S. Patent Appl. U.S. 2009 163545.
20. Yakovlev M.Yu., Romanova O.B., Grizik S.I., Kadushkin A.V., and Granik V.G. Khimiko-Farmatsevticheskii Zhurnal 31 (1997) 44
21. Deyanov A.B., Niyazov R.Kh., Nazmetdinov F.Ya., Syropyatov B.Ya., Kolla V.E., and Konshin M.E. Khimiko-Farmatsevticheskii Zhurnal 25 (1991) 31
22. For a recently published synthesis of new aminonicotinate derivatives using a related protocol, see:. Ravinder M., Sadhu P.S., Santhoshi A., Narender P., Swamy G.Y.S.K., Ravikumar K., and Rao V.J. Synthesis (2010) 573
23. Marco-Contelles J., Pérez-Mayoral M.E., Samadi A., Carreiras M.C., and Soriano E. Chem. Rev. 109 (2009) 2652
24. 2O: C, 56.56; H, 5.42; N, 14.13. Found: C, 56.21; H, 5.69; N, 14.35}, have been synthesized (the details will be further reported in a full paper), and their AChE/BuChE inhibition activities measured as usual. These data have been incorporated in Chart 1. Very interestingly, compounds 6 and 7 are less potent AChEI than ester 2, and inactive for BuChE inhibition.